Label-free serum proteomics and multivariate data analysis identifies biomarkers and expression trends that differentiate Intraductal papillary mucinous neoplasia from pancreatic adenocarcinoma and healthy controls

Translational Medicine Communications

Ari Ristimäki¹  Hanna Seppänen²  Heini Nieminen³  Caj Haglund³  Mayank Saraswat⁴  Risto Renkonen⁴  Sakari Joenvaara⁴  Tiialotta Tohmola⁵ 

[1] 0000 0000 9950 5666, grid.15485.3d, Department of Pathology, Research Programs Unit and HUSLAB, Helsinki University Hospital and University of Helsinki, Helsinki, Finland;0000 0004 0410 2071, grid.7737.4, Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland;0000 0004 0410 2071, grid.7737.4, Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland;0000 0004 0410 2071, grid.7737.4, Translational Cancer Biology Program, Research Programs Unit, University of Helsinki, Helsinki, Finland;0000 0004 0410 2071, grid.7737.4, Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland;0000 0000 9950 5666, grid.15485.3d, HUSLAB, Helsinki University Hospital, Helsinki, Finland;0000 0004 0410 2071, grid.7737.4, Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland;0000 0004 0410 2071, grid.7737.4, Department of Biosciences, University of Helsinki, PO Box 65, 00014, Helsinki, Finland;

关键词: IPMN;    Low-grade dysplasia;    Pancreatic carcinoma;    Serum proteomics;    UDMS;   

DOI  :  10.1186/s41231-019-0037-4

来源: publisher

【 摘 要 】

BackgroundIntraductal Papillary Mucinous Neoplasia (IPMN) are potentially malignant cystic tumors of the pancreas. IPMN can progress from low to moderate to high grade dysplasia and further to IPMN associated carcinoma. Often the difference between benign and malignant nature of the IPMN is not clear preoperatively. We aim to elucidate molecular expression patterns of various grades of IPMN and pancreatic carcinoma. Additionally we suggest potential novel biomarkers to differentiate IPMN from healthy individuals and pancreatic carcinoma to enable early detection as well as help in differential diagnosis in future.MethodsWe have performed retrospective label-free proteomic analysis of the serum samples from 44 patients with various grades of benign IPMN or IPMN associated carcinoma and 11 healthy controls. Proteomic data was further analyzed by various multivariate statistical methods. Four groups of samples (low-grade, high-grade IPMN, pancreatic carcinoma and age- and sex-matched healthy controls) were compared with ANOVA. Orthogonal projections to latent structures-discriminant analysis (OPLS-DA) modeling gave S-plot for feature selection. Stringently selected potential markers were further evaluated with ROC curve analysis and area under the curve was calculated. Differentially expressed proteins were used for pathway analysis. Linear trend analysis (Mann Kendall test) was used for identifying significant increasing or decreasing trends from healthy-low grade-high grade IPMN-pancreatic carcinoma.ResultsBased on protein expression (436 proteins quantified), PCA separated most sample groups from each other. S-Plot selected biomarker panels with moderate to very high AUC values for differentiating controls from Low-, High-Grade IPMN and carcinoma. Linear trend analysis identified 12 proteins which were consistently increasing or decreasing trend among the groups. We found potential biomarkers to differentiate healthy controls from different degrees of dysplasia and pancreatic carcinoma. These biomarkers can classify IPMN, carcinoma and healthy controls from each other which is an unmet clinical need. Data are available via ProteomeXchange with identifier PXD009139.ConclusionKininogen-1 was able to differentiate healthy persons from low and high-grade IPMN. Retinol binding protein-4 could classify the low-grade IPMN from pancreatic carcinoma. Twelve proteins including apolipoproteins and complement proteins had significantly increasing or decreasing trends from healthy to low to high-grade IPMN to pancreatic carcinoma.

【 授权许可】

CC BY